Acrivon Therapeutics, INC

Acrivon Therapeutics stockholders approved an amended equity incentive plan and elected two Class I directors at the 2026 annual meeting.

Acrivon Therapeutics reported Q1 2026 financial results, highlighting progress in its oncology programs ACR-368 and ACR-2316, with cash runway extending into Q3 2027.

Acrivon Therapeutics announced positive clinical trial results for ACR-368 in endometrial cancer and ACR-2316 in lung cancer, alongside a cash runway into Q2 2027.

Acrivon Therapeutics presented positive interim Phase 2b data for ACR-368 in endometrial cancer, particularly in the serous subtype, highlighting significant objective response rates and a favorable safety profile.

Acrivon Therapeutics presented positive clinical data for its lead oncology candidates, ACR-368 and ACR-2316, alongside updates on its AP3 platform and a new development candidate, ACR-6840.

Acrivon Therapeutics announces positive Phase 2b clinical data for ACR-368 in endometrial cancer, initial Phase 1 data for ACR-2316, nominated a new development candidate ACR-6840, and reported preliminary cash of $119 million, extending its operational runway into Q2 2027.

Acrivon Therapeutics reports Q1 2026 results, with continued investment in R&D and a focus on advancing its oncology pipeline, while managing cash runway.

Acrivon Therapeutics, Inc. reported positive clinical data for its lead drug candidates ACR-368 and ACR-2316, while extending its cash runway into Q2 2027 despite continued operating losses.

Acrivon Therapeutics reported increased net losses and cash burn in Q2 2025, while advancing its lead oncology drug candidates ACR-368 and ACR-2316 with positive clinical data.

Acrivon Therapeutics reports a net loss of $19.7 million for Q1 2025, advances clinical programs, and anticipates funding operations into Q2 2027.

Acrivon Therapeutics announced positive clinical data for its lead drug candidate, ACR-368, and progress in its pipeline development during the third quarter of 2024.

Acrivon Therapeutics announced positive initial clinical data from its Phase 2 trial of ACR-368 and provided a financial update, including a private placement that extends their cash runway into the second half of 2026.

Acrivon Therapeutics' 2025 annual report details significant clinical advancements for its oncology pipeline, including positive interim data for ACR-368 in endometrial cancer and progress for ACR-2316, alongside continued operating losses and a need for future funding.

Acrivon Therapeutics' 10-K filing highlights the company's focus on precision oncology, positive clinical data for ACR-368 in endometrial cancer, and advancements in its AP3 platform.

Acrivon Therapeutics details its common and preferred stock structure, voting rights, and anti-takeover provisions in a recent SEC filing.

Mary Miller, Chief Legal Officer of Acrivon Therapeutics, Inc., sold 573 shares of common stock on July 21, 2026 for $1.76 per share.

Acrivon Therapeutics, Inc. executives Peter Blume-Jensen and Kristina Masson reported transactions related to their beneficial ownership of company stock.

RA Capital Management reports a restricted stock unit grant to director Derek DiRocco for Acrivon Therapeutics, Inc.

Michael John Tomsicek, a Director at Acrivon Therapeutics, Inc., acquired 9,366 restricted stock units (RSUs) on May 18, 2026.

Acrivon Therapeutics Director Sharon Shacham acquired 9,366 restricted stock units (RSUs) on May 18, 2026, which are set to vest on May 18, 2027.

Acrivon Therapeutics Director Palani Santhosh acquired 9,366 restricted stock units (RSUs) on May 18, 2026, which are set to vest on May 18, 2027.

Acrivon Therapeutics, Inc. has issued its proxy statement for the 2026 Annual Meeting of Stockholders, scheduled for June 17, 2026, to elect directors and ratify auditor appointment.

Acrivon Therapeutics announces its annual stockholders meeting to be held virtually on June 13, 2025, focusing on director elections and auditor ratification.

Acrivon Therapeutics announces its 2025 Annual Meeting of Stockholders to be held virtually on June 13, 2025, featuring the election of Class III directors and ratification of the independent auditor.

Acrivon Therapeutics will hold its annual meeting of stockholders on June 20, 2024, to elect directors and ratify the appointment of PricewaterhouseCoopers LLP as its independent accounting firm.

Acrivon Therapeutics announces its 2024 Annual Meeting of Stockholders to be held virtually on June 20, 2024, featuring the election of Class II directors and ratification of the independent auditor.

RA Capital Management acquired 3,888,888 shares of Acrivon Therapeutics in an at-the-market offering for approximately $7 million.

RA Capital Management and its affiliates have reported a dilution of their beneficial ownership in Acrivon Therapeutics, Inc. to 21.6% due to an increase in outstanding shares, not through share disposition.

Citadel Advisors and related entities report a negligible beneficial ownership of 13 shares in Acrivon Therapeutics.

Citadel and its affiliates, including Kenneth Griffin, have disclosed a combined beneficial ownership of 5.5% in Acrivon Therapeutics, Inc. common stock.

Citadel and its affiliates, including Kenneth Griffin, report a 4.9% passive beneficial ownership in Acrivon Therapeutics, Inc. as of September 30, 2025.

Sands Capital Life Sciences Pulse Fund II, L.P. and affiliates reported a 6.8% beneficial ownership stake in Acrivon Therapeutics, Inc.

Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. have reported a complete divestment of their beneficial ownership in Acrivon Therapeutics, Inc., holding 0.0% of common stock as of June 2, 2025.

Citadel Advisors LLC and affiliated entities, including Kenneth Griffin, have disclosed a 6.0% beneficial ownership stake in Acrivon Therapeutics, Inc. as of March 31, 2025.